Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 3/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.30 |
| ▸ | NEK2 | P51955 | 6/20 | 0.30 |
| ▸ | PLK1 | P53350 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310509 | 0.89 | CDK2 (0.32) | CDK2CDK9USP1WDR48 | |
| SCHEMBL24309262 | 0.86 | CDK2 (0.32) | CDK2CDK9USP1WDR48 | |
| SCHEMBL29566589 | 0.85 | SCN9A (0.37) | SOS1FLT4KDRCDK2CDK9 | |
| SCHEMBL24309736 | 0.83 | CDK2 (0.32) | CDK2CDK9USP1WDR48 | |
| SCHEMBL24309684 | 0.82 | MET (0.34) | SOS1 | |
| SCHEMBL24310447 | 0.78 | USP1 (0.33) | USP1WDR48 | |
| SCHEMBL24309230 | 0.76 | EGFR (0.32) | — | |
| SCHEMBL24309699 | 0.76 | F2 (0.32) | — | |
| SCHEMBL24309467 | 0.75 | EGFR (0.37) | CDK9 | |
| SCHEMBL24310457 | 0.75 | BRD4 (0.39) | CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |